Intrinsic Imaging Awarded Phase III Clinical Trial Focused on Brain Metastases of Non-Small Cell Lung Cancer (NSCLC)

Intrinsic Imaging's team has extensive therapeutic experience evaluating various therapies to treat brain metastases from non-small cell lung cancer and will perform over 6000 neuroradiology assessments throughout the trial.

Bolton, MA / San Antonio, TX

Bolton, MA / San Antonio, TX — March 29, 2017 — Intrinsic Imaging, LLC, an FDA audited and ISO certified medical imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that it has been awarded another international phase III clinical trial for the evaluation of a novel treatment for metastatic non-small cell lung cancer (NSCLC) to the brain.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, study management, protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. Intrinsic Imaging will also perform over 6000 neuroradiology assessments of the patients' tumor response to therapy.

Of its team of 70 full-time radiologists, Intrinsic Imaging's neuroradiology team consists of 9 full-time board-certified, fellowship trained neuroradiologists who are experts in the evaluation of brain metastases from various primaries including non-small cell lung cancer.

"Intrinsic Imaging's team has extensive therapeutic experience in evaluating therapies that treat metastatic non-small cell lung cancer of the brain," said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. "Our neuroradiology experience, coupled with our exceptional operational expertise, allows us to provide unprecedented imaging core lab services on this pivotal clinical trial."

Lung cancer is the leading cause of cancer death across the globe. Among tumor types, lung cancers account for the highest number of brain metastases, with 25% of patients being affected at some time in their disease course.

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 750 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com